logo
Ozempic Now FDA-Approved for Kidney Disease—Here's What to Know

Ozempic Now FDA-Approved for Kidney Disease—Here's What to Know

Yahoo13-02-2025

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to taking Ozempic: It may help manage chronic kidney disease (CKD). On January 28, the U.S. Food and Drug Administration (FDA) approved the GLP-1 drug to reduce the risk of kidney disease worsening into kidney failure after the success of a clinical trial. To learn more about the effects of Ozempic on chronic kidney disease, keep scrolling.
The FLOW phase 3b kidney outcomes trial, which was published in The New England Journal of Medicine, was trying to solve the problem of diabetes being a risk factor for kidney disease by using semaglutide.
According to Richard E. Pratley, MD, medical director at the AdventHealth Diabetes Institute in Orlando, FL, and co-chair of the FLOW clinical trial, there have been new classes of medications released in the last several years to slow down kidney disease progression. While he says these have been helpful, many people still progress to kidney failure.
Before the FLOW trial, various studies demonstrated that 'drugs like liraglutide, semaglutide and dulaglutide were effective at reducing the risk for cardiovascular events such as heart attacks, strokes and cardiovascular death,' says Dr. Pratley, 'But they also seem to indicate that there is a benefit on kidney disease progression.'
Those studies weren't meant for kidney disease and had very few patients with the condition. However, they jump-started the need to look into the effects of those drugs as a way to help treat CKD.
The FLOW trial began in 2019 as a global study with about 3,500 participants from 28 countries who had a median age of 65. 'Everyone was randomized to semaglutide or a placebo, all had chronic kidney disease or specific criteria and all had type 2 diabetes,' says Dr. Pratley. In addition to taking Ozempic, patients were also being treated with medication to manage high blood pressure, including angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs).
After more than three years, 'There was about a 24 percent reduction in progression of chronic kidney disease,' says Dr. Pratley. That includes 'kidney failure, progression of the EGFR decline and also cardiovascular death.'
How else did Ozempic help people with diabetes and kidney disease? Kidney failure, a decline in kidney function and incidences of death were significantly reduced. Dr. Pratley adds that the risk for major adverse cardiovascular events also decreased significantly.
Before Ozempic was developed, Dr. Pratley explains that other studies used SGLT 2 inhibitors for CKD and showed benefits in patients who didn't have diabetes. However, 'there is no comparable data with the semaglutide. At the moment, the label is just for people with type 2 diabetes and chronic kidney disease,' he says. That means Ozempic is not FDA-approved to treat chronic kidney disease on its own. Dr. Pratley advises talking to your doctor about treatment options but hopes that more studies will demonstrate the benefits of Ozempic for those with CKD.
Results of the FLOW trial showed a reduction in glucose and A1C levels, as well as some evidence for reductions in lipid values, LDL, total cholesterol and blood pressure. But Dr. Pratley says that none of these things are able to fully explain the benefit of GLP-1 drugs for CKD. 'We think it's more likely to be a direct mechanism that perhaps has something to do with inflammation,' he explains. 'There is evidence for decreased inflammation following treatment, and the C-reactive protein levels are about 50 percent lower.'
While semaglutide has shown promise in treating patients with chronic kidney disease and type 2 diabetes, Novo Nordisk is continuing its research. The drug manufacturer is currently conducting a different study to understand the exact ways that GLP-1 drugs can reduce CKD risks.
For more health content
Bariatric Surgery vs. Ozempic: 1 Woman Shares Her Surgery Success Story
How Long Does It Take for Ozempic To Work? A Doctor Shares Tips to Speed Weight Loss
NK2R: The Ozempic Alternative That Curbs Appetite and Burns Fat Without Side EffectsThis content is not a substitute for professional medical advice or diagnosis. Always consult your physician before pursuing any treatment plan.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26

Yahoo

time30 minutes ago

  • Yahoo

TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26

Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential. It reported interim Week 26 data from its Phase 2 COACH Trial, confirming that combining TransCon hGH (lonapegsomatropin) with TransCon CNP (navepegritide) raised annualized growth velocity (AGV) and height Z-scores in children with achondroplasia. A close-up view of a hand manipulating a syringe while delivering TransCon CNP into a tumor. A mean AGV of 9.14 cm/year and a +0.53 Z-score rise were attained by treatment-naïve youngsters (N=12). Children (N=9) treated with TransCon CNP in the past achieved an AGV of 8.25 cm/year with a +0.44 Z-score improvement. The majority of side effects were modest, and safety remained consistent with monotherapies. The COACH Trial is the first to assess this combination in kids between the ages of two and eleven. While TransCon CNP is undergoing FDA priority review, TransCon hGH is approved as SKYTROFA® for juvenile growth hormone insufficiency. The treatment focuses on the FGFR3-CNP signaling imbalance that is at the heart of achondroplasia, a disorder that affects more than 250,000 people worldwide. It is anticipated that the results of week 52 and a scheduled Phase 3 trial in Q4 2025 will further clarify efficacy and long-term benefits. The biopharmaceutical business Ascendis Pharma A/S (NASDAQ:ASND) uses its TransCon technology platform to significantly improve patient outcomes. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.

Enoki Mushrooms Recalled Nationwide for Potential Listeria Contamination—Here's What to Know
Enoki Mushrooms Recalled Nationwide for Potential Listeria Contamination—Here's What to Know

Yahoo

time37 minutes ago

  • Yahoo

Enoki Mushrooms Recalled Nationwide for Potential Listeria Contamination—Here's What to Know

If you've recently grabbed some enoki mushrooms, you'll want to check your fridge. Packages of Enoki mushrooms from Hofood99 Inc. have been recalled by the FDA due to potential contamination with Listeria. The mushrooms that were recalled were sold nationwide and packaged in green plastic. They were in a 200-gram package with a UPC Barcode 6 976532 310051 on the back label, distributed by Hofood99 Inc., 21903 56th Ave., Oakland Gardens, NY 11364. Related: Are Food Recalls Really on the Rise? A Food Microbiologist Weighs In So far, no illnesses have been reported in relation to the mushrooms, but Listeria monocytogenes is a common cause of food safety recalls. Listeria can cause high fevers, severe headache, stiffness, nausea, and diarrhea in healthy people—but infection with listeria can cause stillbirth or miscarriage in pregnant women, and deadly infections in young children, the elderly, and people with weakened immune systems. Related: How to Wash Every Type of Mushroom So They're Safe to Eat If you have the affected products, do not eat them. You can destroy the mushrooms or return them to the store for a full refund. If you have any questions, you can contact Hofood99 at 917-756-9833, between 9 a.m. and 2 p.m., Monday to Friday. Read the original article on Real Simple

Illinois becomes first state to require that all insurance covers Alzheimer's treatment
Illinois becomes first state to require that all insurance covers Alzheimer's treatment

Yahoo

time37 minutes ago

  • Yahoo

Illinois becomes first state to require that all insurance covers Alzheimer's treatment

SPRINGFIELD, Ill. (WCIA) — Illinois is making a major expansion in patient care and access to new treatment for Alzheimer's, thanks to a new state law taking effect in July 2025. Gov. J.B. Pritzker signed a bill that will require state health insurance to cover U.S. Food and Drug Administration (FDA) approved medicine to slow down Alzheimer's and other related diseases. SEE ALSO: New Illinois laws and tax changes set to kick in on July 1, 2025 Some Alzheimer's patients will no longer have to go through step therapy — a process where insurers require patients to try and test less expensive drugs before covering the actual medication prescribed by their doctor. The Alzheimer's Association Illinois Chapter, which has been a forefront advocate for this, called the law 'groundbreaking.' 'For people living with Alzheimer's, slowing the progression of the disease changes someone's life — not only that individual's life, but the lives of their caregivers and all those around them, family and friends,' said David Olson, Director of State Affairs at the Alzheimer's Association Illinois Chapter. This coverage will also include diagnostic testing at the doctor's request. This ensures patients can access an accurate diagnosis before even starting the treatment. In 2020, there were 230,000 seniors with Alzheimer's disease or a related dementia in the state, and according to the Illinois Department of Health, that number is expected to increase to 260,000 this year. With the rise in medical costs, insurance coverage is essential for most families. Bill creating Office of State Public Defender heads to Pritzker's desk The bill's sponsor in the House, Rep. Mary Gill (D-Chicago), said with dementia, time is always at the essence. 'When it comes to slowing Alzheimer's and other dementias, every moment counts,' Gill said. 'We can't waste time on insurance gimmicks like step therapy to save a few bucks, which is why I'm thankful for the strong advocacy and bipartisan support this legislation received.' Other private insurance plans will also begin covering FDA-approved treatment starting in 2027. 'We worked collaboratively with the insurance industry on this legislation,' Olson said. 'We were able to find and agree upon language here that expands access in a way that also isn't increasing cost to consumers.' Currently, there are two types of treatments for Alzheimer's approved by the FDA. One is Lecanemab, and the other is Donanemab. These will not end the disease, as there is currently no cure for Alzheimer's. This law makes Illinois the first state to require such treatment, and advocates said they hope other states will follow its lead. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store